IMPILO HOLDING AB
IMPILO HOLDING AB is a Series C+ and buyout fund in the US, Nordic and Europe writing $50M–$200M checks into pharmaceuticals, medical-technology and healthcare-services.
- Stages
- Series C+, buyout
- Sectors
- pharmaceuticals, medical-technology, healthcare-services
- Check size
- $50M–$200M
- Invests in
- US-wide, Nordic, Europe
- Actively investing
- Yes
- Founded
- 2017
- Assets under management
- EUR 2B
- Website
- impilo.se
Thesis
Impilo is a Nordic investment company founded in 2017, headquartered in Stockholm, Sweden, focusing exclusively on pharmaceutical, medical technology, healthcare services, and related health industries. Their core investment thesis is that healthcare businesses with positive health outcomes, strong ESG performance, and high growth potential lead to better companies and superior returns. Their strategy is guided by the 'Impilo Health Diamond,' focusing on improving care quality, increasing availability, lowering cost, and preventing the need for care. They primarily target private majority investments in companies with enterprise values between EUR 50 million and EUR 200 million, seeking those with potential to double operating profit within five years. While primarily Nordic, they also invest across Europe and have some US exposure. Impilo has raised significant capital, with Fund II closing at EUR 700 million and total AUM exceeding EUR 2 billion (SEK 10 billion). Their first buyout fund in 2017 had a size of $391 million.
Common questions
Does IMPILO HOLDING AB invest at the Series C+ stage?
Yes. IMPILO HOLDING AB lists Series C+ and buyout among the stages it invests in.
What check size does IMPILO HOLDING AB write?
IMPILO HOLDING AB writes $50M–$200M checks.
Where does IMPILO HOLDING AB invest?
IMPILO HOLDING AB invests in the US, Nordic and Europe.